-
Bupa fined A$35m in Australia for misleading customers in health insurance claims
Bupa admits to misleading thousands of health insurance customers and unconscionably denying legitimate claims over more than five years.
-
Clearing firm fined for surveillance lapses related to potentially manipulative trading
FINRA outlined failure to implement effective supervisory and surveillance practices for trading and business communications recordkeeping.
-
FINRA disciplinary action update 2025/24
Disciplinary decisions issued June 21 – 27, 2025.
-
CVS Caremark’s $95m penalty for Medicare drug overbilling
Whistleblower alleged Caremark reported higher costs of drugs to the government than it paid pharmacies for dispensing Medicare Part D drugs.
-
Apple makes last-minute changes to App Store policies in EU to avoid fine
Announcement is latest episode in tense stand-off between European regulators and US tech giants.
-
OPINION: US bank supervisors downplay reputational risk – but it won’t go away
Maybe reputation has loomed too large in risk assessment but, says Julie DiMauro, it would be unwise to disregard it entirely.
-
Ex-CEO sentenced in first prosecution for stock sales via 10b5-1 trading plans
DOJ says he avoided $12.5m+ in losses by trading pursuant to two Rule 10b5-1 trading plans while allegedly in possession of MNPI.
-
FINRA disciplinary action update 2025/23
Disciplinary decisions issued June 14 – 20, 2025.